Oral Cladribine B-cell Study
NCT06415864 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10
Last updated 2026-02-04
Summary
To study the impact of cladribine on peripheral and intrathecal B-cell, plasma cells, T cells and Tregs
Conditions
Sponsors & Collaborators
-
Queen Mary University of London
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-07-01
- Primary Completion
- 2024-01-31
- Completion
- 2024-01-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis
NCT04711148 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
CLARITY Extension Study
NCT00641537 ·Status: COMPLETED ·Phase: PHASE3
-
Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).
NCT05961644 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis
NCT04695080 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Effect of Cladribine Treatment on Microglial Activation in the CNS
NCT04239820 ·Status: ACTIVE_NOT_RECRUITING
-
A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)
NCT00436826 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients
NCT05902429 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Effects of Ocrelizumab on B-cell Tolerance Defect in Relapsing Multiple Sclerosis
NCT04261790 ·Status: COMPLETED ·Phase: PHASE4
-
Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)
NCT03961204 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)
NCT03933202 ·Status: COMPLETED
-
Effects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis
NCT06495593 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
Consolidation Therapy With Cladribine in Relapsing Multiple Sclerosis Patients
NCT06854094 ·Status: ACTIVE_NOT_RECRUITING
-
Efficacy of L-carnitine Versus Placebo in the Treatment of Fatigue in Multiple Sclerosis
NCT01149525 ·Status: COMPLETED ·Phase: PHASE3
-
Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)
NCT04997148 ·Status: COMPLETED
-
CDP323 Biomarker Study
NCT00726648 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Amantadine and Transcranial Magnetic Stimulation for Treating Fatigue in Multiple Sclerosis
NCT05809414 ·Status: RECRUITING ·Phase: PHASE3
-
Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis
NCT01585766 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
NCT00109161 ·Status: COMPLETED ·Phase: PHASE2
-
12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients
NCT00616733 ·Status: COMPLETED ·Phase: PHASE1
-
Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)
NCT05797740 ·Status: ACTIVE_NOT_RECRUITING
-
Long Term Safety and Efficacy Study of Tolebrutinib (SAR442168) in Participants With Relapsing Multiple Sclerosis
NCT03996291 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
NCT07067463 ·Status: RECRUITING ·Phase: PHASE3
-
A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis
NCT02576717 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis
NCT01541618 ·Status: COMPLETED
-
Short-term B-cell Depletion in Relapsing Multiple Sclerosis
NCT03853746 ·Status: COMPLETED ·Phase: PHASE4